Wire report
‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug
Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors About two years ago, Henry, who is 6ft 3in, weighed 210lb, which meant he was only slightly overweight, according to the Centers for Disease Control and Prevention body mass index. Still, the thirtysomething who lives in the Pacific north-west had hypertension, sleep apnea and body image issues, so he started taking the weight-loss drug Ozempic. While he dropped pounds, he experienced constipation, a common side-effect, so he wanted to try retatrutide, another peptide which not only targets GLP-1 but two other hormone receptors as well. Continue reading...
coverage / Wire report
Get updates, read source context, send useful records, share the story, or support the reporting work from the reading page.
Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors About two years ago, Henry, who is 6ft 3in, weighed 210lb, which meant he was only slightly overweight, according to the Centers for Disease Control and Prevention body mass index. Still, the thirtysomething who lives in the Pacific north-west had hypertension, sleep apnea and body image issues, so he started taking the weight-loss drug Ozempic. While he dropped pounds, he experienced constipation, a common side-effect, so he wanted to try retatrutide, another peptide which not only targets GLP-1 but two other hormone receptors as well. Continue reading...
Check the original link, updates, and responses when a detail is contested.
Open topic or search related wording such as records, sources, agencies, dates, and locations.
What happened
According to The Guardian’s source item, ‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug, Retatrutide, not yet approved by the FDA, is the latest wonder drug to shed pounds despite warnings from doctors About two years ago, Henry, who is 6ft 3in, weighed 210lb, which meant he was only slightly overweight, according to the Centers for Disease Control and Prevention body mass index. Still, the thirtysomething who lives in the Pacific north-west had hypertension, sleep apnea and body image issues, so he started taking the weight-loss drug Ozempic. While he dropped pounds, he experienced constipation, a common side-effect, so he wanted to try retatrutide, another peptide which not only targets GLP-1 but two other hormone receptors as well. Continue reading…
Context
The development sits in VINI’s Markets file for readers following markets, companies, finance, insurance, public policy, and economic signals. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-08-31T12:00:24+00:00.
What to watch
Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.
Source
Primary source: ‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drug via The Guardian. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.
Keep following
This file can keep developing
vininews.com uses reader tips, public records, right-of-reply requests, corrections, and follow-up reporting to keep important stories current.
Support and subscriptions never buy coverage, placement, suppression, or corrections.
This VINI report keeps the original publisher link available and does not republish third-party article bodies without rights clearance. 1 reference listed.
Source links
- ‘Who knows what they’re taking?’: people risk the gray market for the newest weight-loss drugThe Guardian - 2026-08-31T12:00:24+00:00
Reader comments
Moderated discussion
Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.
No approved comments yet.
Substantive, civil comments can be submitted by approved account holders.